Home › Trials › NCT03631225

Evaluating Vectra for guiding treatment in rheumatoid arthritis

Vectra InVolved Informed Decision Outcome Study (VIVID): A Prospective Randomized Controlled Trial Evaluating the Effect of Guided Care With Vectra Compared to Treatment as Usual in Patients With Rheumatoid Arthritis

Sequenom, Inc. · NCT03631225

This study is testing if the Vectra blood test can help doctors make better treatment decisions for people with rheumatoid arthritis compared to regular care.

Quick facts

Study typeObservational
Enrollment1500 (estimated)
Ages18 Years and up
SexAll
SponsorSequenom, Inc. (industry)
Drugs / interventionstocilizumab, sarilumab
Locations30 sites (La Mesa, California and 29 other locations)
Trial IDNCT03631225 on ClinicalTrials.gov

What this trial studies

This study aims to assess the effectiveness of the Vectra blood test in guiding treatment decisions for patients with rheumatoid arthritis (RA) compared to standard care. Vectra analyzes 12 biomarkers to produce a score that predicts disease progression, which may help in optimizing treatment strategies. The study will involve patients who are already receiving treatment for RA and will evaluate the clinical benefits of using Vectra in a real-world setting. By comparing outcomes between those guided by Vectra and those receiving usual care, the study seeks to provide insights into improving RA management.

Who should consider this trial

Good fit: Ideal candidates are adults aged 18 and older diagnosed with rheumatoid arthritis who have a CDAI score greater than 10 and are currently on DMARD therapy.

Not a fit: Patients currently taking anti-IL-6R drugs or those with contraindications to new RA therapies may not benefit from this study.

Why it matters

Potential benefit: If successful, this approach could lead to better treatment outcomes and reduced joint damage for patients with rheumatoid arthritis.

How similar studies have performed: While the use of biomarkers in RA management is established, the specific application of Vectra in this context is being evaluated for the first time in a real-world setting.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* ≥ 18 years old at screening visit
* Diagnosed with RA according to 1987 or 2010 criteria of the American College of Rheumatology
* At the time of the pre-baseline visit, patient has a CDAI score of \>10
* Currently taking one or more non-biologic or biologic DMARD at screening and for at least the 3 months prior to screening
* Visit at time of screening scheduled as part of routine care
* Subject and/or physician willing to consider treatment change at screening
* No expectation of imminent treatment change at screening or baseline visit

Exclusion Criteria:

* Currently taking an anti-IL-6R drug (tocilizumab, sarilumab)
* Any contraindication, administrative barrier, or financial limitation (e.g. no insurance coverage) that makes it impossible for subject to receive at least one new biologic or JAKi therapy for RA
* Active infection
* History of malignancy within the past 5 years or any evidence of persistent malignancy, except fully excised basal cell or squamous cell carcinomas of the skin, or cervical carcinoma in situ that has been treated or excised in a curative procedure
* Current enrollment in another clinical trial
* Any condition or circumstance that makes it likely the patient will not be able to complete the trial

Where this trial is running

La Mesa, California and 29 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.

View on ClinicalTrials.gov →

Conditions: Rheumatoid Arthritis, Vectra, Radiographic Projections

Last reviewed 2026-05-15 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.